We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
CABOMETYX (Ipsen Pty Ltd)
Product name
CABOMETYX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
149 (255 working days)
Active ingredients
cabozantinib (S)-malate
Registration type
EOI
Indication
CABOMETYX is indicated for the treatment of adult patients with locally advanced/unresectable or metastatic, well-differentiated extra-pancreatic (epNET) or pancreatic (pNET) neuroendocrine tumours who have progressed on at least one prior systemic therapy other than a somatostatin analogue